NASDAQ:PACB Pacific Biosciences of California - PACB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.58 -0.42 (-3.50%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$11.27▼$12.0750-Day Range$7.79▼$12.0252-Week Range$3.85▼$14.20Volume4.57 million shsAverage Volume4.92 million shsMarket Capitalization$2.62 billionP/E RatioN/ADividend YieldN/APrice Target$15.71 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Pacific Biosciences of California MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside35.7% Upside$15.71 Price TargetShort InterestBearish10.70% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 3 Articles This WeekInsider TradingSelling Shares$742,461 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.37) to ($1.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector561st out of 1,028 stocksAnalytical Instruments Industry14th out of 27 stocks 3.3 Analyst's Opinion Consensus RatingPacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.71, Pacific Biosciences of California has a forecasted upside of 35.7% from its current price of $11.58.Amount of Analyst CoveragePacific Biosciences of California has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.70% of the outstanding shares of Pacific Biosciences of California have been sold short.Short Interest Ratio / Days to CoverPacific Biosciences of California has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Pacific Biosciences of California has recently decreased by 1.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPacific Biosciences of California does not currently pay a dividend.Dividend GrowthPacific Biosciences of California does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PACB. Previous Next 2.4 News and Social Media Coverage News SentimentPacific Biosciences of California has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pacific Biosciences of California this week, compared to 2 articles on an average week.Search Interest18 people have searched for PACB on MarketBeat in the last 30 days. This is an increase of 64% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $742,461.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of Pacific Biosciences of California is held by insiders.Percentage Held by Institutions92.88% of the stock of Pacific Biosciences of California is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pacific Biosciences of California are expected to grow in the coming year, from ($1.37) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacific Biosciences of California is -8.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacific Biosciences of California is -8.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPacific Biosciences of California has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pacific Biosciences of California (NASDAQ:PACB) StockPacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.Read More Receive PACB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter. Email Address PACB Stock News HeadlinesFebruary 2, 2023 | finance.yahoo.comPacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023January 29, 2023 | americanbankingnews.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Hold" by AnalystsFebruary 4, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 26, 2023 | finance.yahoo.comPacific Biosciences of California (NASDAQ:PACB) shareholder returns have been massive, earning 313% in 5 yearsJanuary 13, 2023 | finance.yahoo.comPacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"January 12, 2023 | finance.yahoo.comPacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower SalesJanuary 9, 2023 | benzinga.comWhy Pacific Biosciences Of California Shares Are Trading Higher TodayJanuary 9, 2023 | finance.yahoo.comPacBio and the University of Tokyo Announce Bioinformatics Applications CollaborationFebruary 4, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 9, 2023 | finance.yahoo.comPacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022December 28, 2022 | finance.yahoo.comPacBio to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 22, 2022 | finance.yahoo.comShould You Add Pacific Biosciences of California (PACB) to Your Portfolio?December 21, 2022 | seekingalpha.comPacific Biosciences: New Products Set To Drive Strong Growth And Margin ImprovementDecember 16, 2022 | benzinga.comPacific Mobile Structures Set to Officially Open its 14-Acre Facility in San Marcos, Texas in Early 2023November 8, 2022 | seekingalpha.comPacific Biosciences of California, Inc. (PACB) Q3 2022 Earnings Call TranscriptNovember 2, 2022 | finance.yahoo.comPacBio Announces that Euan Ashley, M.D., Ph.D., Joseph Puglisi, Ph.D., and Jay Shendure, Ph.D., Join Newly Created Scientific Advisory BoardOctober 27, 2022 | seekingalpha.comPacific Biosciences Of California: Leveraging On Scale And Product DevelopmentOctober 26, 2022 | finance.yahoo.comPacBio To Launch New Gene-Sequencing SystemsOctober 20, 2022 | finance.yahoo.comPacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA DiscoveryOctober 19, 2022 | finance.yahoo.comPacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi SequencingOctober 18, 2022 | finance.yahoo.comPacBio Collaborates with Leading Researchers to Establish Long-Read Variant Frequency ConsortiumSeptember 28, 2022 | finance.yahoo.comPacBio's (PACB) New Method for TR Profiling Now AvailableSeptember 27, 2022 | finance.yahoo.comPacBio Unveils a New Method for Comprehensive, Genome-wide Tandem Repeat AnalysisSeptember 17, 2022 | finance.yahoo.comPacific Biosciences of California, Inc. (PACB)September 16, 2022 | seekingalpha.comPACB Pacific Biosciences of California, Inc.September 7, 2022 | finance.yahoo.comPacBio to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 8, 2022 | finance.yahoo.comWhat Does The Future Hold For Pacific Biosciences of California, Inc. (NASDAQ:PACB)? These Analysts Have Been Cutting Their EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PACB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter. Email Address PACB Company Calendar Last Earnings11/07/2022Today2/04/2023Next Earnings (Confirmed)2/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB CUSIP69404D10 CIK1299130 Webwww.pacb.com Phone(650) 521-8000Fax302-636-5454Employees728Year Founded2004Price Target and Rating Average Stock Price Forecast$15.71 High Stock Price Forecast$40.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+35.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,220,000.00 Net Margins-218.44% Pretax Margin-217.58% Return on Equity-42.03% Return on Assets-15.59% Debt Debt-to-Equity Ratio1.43 Current Ratio11.19 Quick Ratio10.66 Sales & Book Value Annual Sales$130.51 million Price / Sales20.06 Cash FlowN/A Price / Cash FlowN/A Book Value$3.59 per share Price / Book3.23Miscellaneous Outstanding Shares226,110,000Free Float222,943,000Market Cap$2.62 billion OptionableOptionable Beta1.67 Social Links Key ExecutivesChristian O. HenryPresident, Chief Executive Officer & DirectorMark David van OeneChief Operating OfficerSusan G. KimChief Financial OfficerStephen W. TurnerChief Technology OfficerJonas KorlachChief Scientific OfficerKey CompetitorsOlink Holding AB (publ)NASDAQ:OLKCytek BiosciencesNASDAQ:CTKB10x GenomicsNASDAQ:TXGProthenaNASDAQ:PRTAAmylyx PharmaceuticalsNASDAQ:AMLXView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 385,700 shares on 2/2/2023Ownership: 0.000%AtonRa PartnersSold 42,862 shares on 2/2/2023Ownership: 0.039%SG Americas Securities LLCBought 47,790 shares on 2/2/2023Ownership: 0.034%ProShare Advisors LLCBought 3,968 shares on 2/2/2023Ownership: 0.021%Bay Colony Advisory Group Inc d b a Bay Colony AdvisorsBought 1,250 shares on 2/1/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions PACB Stock - Frequently Asked Questions Should I buy or sell Pacific Biosciences of California stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PACB shares. View PACB analyst ratings or view top-rated stocks. What is Pacific Biosciences of California's stock price forecast for 2023? 6 equities research analysts have issued 12-month price targets for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $8.00 to $40.00. On average, they expect the company's stock price to reach $15.71 in the next twelve months. This suggests a possible upside of 35.7% from the stock's current price. View analysts price targets for PACB or view top-rated stocks among Wall Street analysts. How have PACB shares performed in 2023? Pacific Biosciences of California's stock was trading at $8.18 on January 1st, 2023. Since then, PACB shares have increased by 41.6% and is now trading at $11.58. View the best growth stocks for 2023 here. When is Pacific Biosciences of California's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023. View our PACB earnings forecast. How can I listen to Pacific Biosciences of California's earnings call? Pacific Biosciences of California will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its quarterly earnings data on Monday, November, 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The biotechnology company had revenue of $32.31 million for the quarter, compared to the consensus estimate of $35.30 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 42.03% and a negative net margin of 218.44%. What guidance has Pacific Biosciences of California issued on next quarter's earnings? Pacific Biosciences of California updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.30 million-$27.30 million, compared to the consensus revenue estimate of $27.88 million. What is Christian Henry's approval rating as Pacific Biosciences of California's CEO? 2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA). What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." Who are Pacific Biosciences of California's major shareholders? Pacific Biosciences of California's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.36%), Sumitomo Mitsui Trust Holdings Inc. (6.27%), Bourne Lent Asset Management Inc. (0.26%), Simplex Trading LLC (0.00%), State of New Jersey Common Pension Fund D (0.10%) and New York State Common Retirement Fund (0.08%). Insiders that own company stock include Christian O Henry, Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim, Susan K Barnes and William W Ericson. View institutional ownership trends. How do I buy shares of Pacific Biosciences of California? Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $11.58. How much money does Pacific Biosciences of California make? Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.62 billion and generates $130.51 million in revenue each year. The biotechnology company earns $-181,220,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. How many employees does Pacific Biosciences of California have? The company employs 728 workers across the globe. Does Pacific Biosciences of California have any subsidiaries? The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.Read More How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454. This page (NASDAQ:PACB) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.